To counter this, plicamycin has been shown to inhibit Sp1 and concurrently enhance anti-PD-1 immunotherapy by reshaping the TME, suggesting Sp1 inhibition as a promising therapeutic strategy for HPV-related cancers [46]. This evidence concerns the gene SP1 and cancer.